Search
SPP 301
go.drugbank.com/drugs/DB05290InvestigationalSPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy.
NUC B1000
go.drugbank.com/drugs/DB05242Experimental[F3910] eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to diseased cells enabling the cells to carry out dsRNA production internally thereby invoking … On January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its experimental treatment for chronic Hepatitis B virus (HBV) infection.
PRTX-100
go.drugbank.com/drugs/DB05947InvestigationalPRTX-100 is a highly-purified form of Staphylococcal Protein A that binds directly to monocytes and a subset of B-cells that are involved in the development and progression of various autoimmune diseases
Methadyl acetate
go.drugbank.com/drugs/DB01433ExperimentalIllicitIt is used mainly in the treatment of narcotic dependence.
Deramciclane
go.drugbank.com/drugs/DB06512InvestigationalDeramciclane differs from other anti anxiety medications in that it is not a benzodiazepine and so has a different structure and target. … Deramciclane (EGIS-3886) is used for the treatment of a number of anxiety disorders.
Cycrimine
go.drugbank.com/drugs/DB00942ApprovedCycrimine is a drug used to reduce levels of acetylcholine to return a balance with dopamine in the treatment and management of Parkinson's disease.
E-2012
go.drugbank.com/drugs/DB05171ExperimentalE-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.
AN-9
go.drugbank.com/drugs/DB05103Investigationalthan BA in preclinical studies. … Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), exhibited low toxicity and significant anticancer activity in vitro and in vivo.
Synonyms: AN-9Zidesamtinib
go.drugbank.com/drugs/DB21623ApprovedInvestigational[L63808,L63933] Zidesamtinib is selective for ROS1, retains activity in cells carrying the common resistance mutations, and showed antitumor activity in an intracranial model, positioning it for use after … of resistance mutations, particularly the solvent front G2032R substitution, and progression of disease in the brain.
FX06
go.drugbank.com/drugs/DB05685InvestigationalFX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc. … FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells.